


SARS-CoV-2 Sequencing Update 17 September 2021



Supported by the DSI and the SA MRC

Msomi N. Mlisana K. et al. Lancet Microbe 2020

The genomic data presented here are based on South African SARS-CoV-2 sequence data downloaded from GISAID (www.gisaid.org) on 17 September at 08h58




Data license: <https://www.gisaid.org/registration/terms-of-use/>

Elbe, S., and Buckland-Merrett, G. (2017) Data, disease and diplomacy: GISAID's innovative contribution to global health. *Global Challenges*, 1:33-46. DOI: 10.1002/gch2.1018 PMID: 31565258

Shu, Y., McCauley, J. (2017) GISAID: Global initiative on sharing all influenza data – from vision to reality. *EuroSurveillance*, 22(13) DOI: 10.2807/1560-7917.ES.2017.22.13.30494 PMID: PMC5388101

Number of South African genomes deposited on GISAID, by specimen collection week, 2020 and 2021
(N=18 449*)





Total genomes: 18 449
2020 genomes: 6 077
2021 genomes: 12 372

Sequencing data ending epi
week 36 (ending 11 September
2021)

Currently in epi week 37
(ending 18 September 2021)


*This represents the cleaned, de-duplicated dataset of unique sequences. This dataset will be used for all further figures.

GISAID genomes vs total cases, 2020 and 2021 (N=18 449)



All provinces, apart from GP, KZN, and WC, have comparable percentage of overall cases and overall sequenced genomes

Distribution and number of clades in South Africa, 2021 (N= 12 140)




Sequencing data
ending epi week 36
(ending 11
September 2021)

Currently in epi
week 37 (ending 18
September 2021)


Delta came to dominate by end June at >65% , in July at >85% and in August at >90%
C.1.2 present at <3% frequency since March

Prevalence of Variants of Concern (VOC) and Variants of Interest (VOI) in **May – early September 2021** sequences, South Africa


May (N = 1143)




June (N = 2931)





July (N = 3626)



August (N = 1034)









September (N = 44)



Beta variant dominated in May, while the Delta variant dominated in June-August in South Africa


Genomes sequenced from specimens collected in May to mid-August 2021 (epiweeks 18 – 37) from KwaZulu-Natal, Gauteng, Western Cape Provinces



— cases Delta (21A) Beta (20H, V2) Alpha (20I, V1) C.1.2 (20D) Kappa (21B) Eta (21D) 20A 20B 20C 20D unassigned 19B







Beta dominates in all provinces in May, however following its detection in week 18, Delta rapidly begins to dominate in all three provinces by mid-June and continues to dominate in July and August

Genomes sequenced from specimens collected in May to mid-August 2021 (epiweeks 18 – 37) from Eastern Cape, Limpopo and North-West Provinces



Delta variant dominating in Eastern Cape, Limpopo and North-West Provinces

Genomes sequenced from specimens collected in May to mid-August 2021 (epiweeks 18 – 37) from Free State, Mpumalanga and Northern Cape Provinces










— cases Delta (21A) Beta (20H, V2) Alpha (20I, V1) C.1.2 (20D) Kappa (21B) Eta (21D) 20A 20B 20C 20D unassigned 19B

Despite small number of genomes, Delta dominating in FS, MP and NC provinces

C.1.2 (n=150 in SA) in May – August 2021 by epiweek








Number of C.1.2 samples indicated above bar



C.1.2 has now been detected in all provinces. 11 sequences have been detected in the Free State, 10 in KwaZulu-Natal, and 7 in Mpumalanga.


C.1.2 (n=150 in SA) in May – August 2021 by epiweek

Number of C.1.2 samples indicated above bar



The Western Cape has 7 sequences, the North West has 4, and the Eastern Cape has 3 detections of C.1.2.


C.1.2 growth compared to Beta and Delta



C.1.2 is being continually monitored and is currently only detected at low levels

Summary

- Delta continues to dominate in all provinces from specimens collected in August
- Overall diversity of lineages decreased as Delta became dominant
- Lambda and Mu variants not detected in South Africa
- Mutated C.1.2 lineage has now been detected in all provinces of South Africa
 - The frequency of C.1.2 at less than 3% of genomes



UNIVERSITEIT VAN PRETORIA
UNIVERSITY OF PRETORIA
YUNIBESITHI YA PRETORIA



UNIVERSITEIT
YUNIVESITHI
STELLENBOSCH
UNIVERSITY



UNIVERSITY OF CAPE TOWN
YUNIVESITHI YASEKAPA • UNIVERSITEIT VAN KAAPSTAD



science & innovation
Department:
Science and Innovation
REPUBLIC OF SOUTH AFRICA




WITS
UNIVERSITY



UNIVERSITY OF
KWAZULU-NATALTM
INYUVESI
YAKWAZULU-NATALI




UKZN-Inkosi Albert Luthuli Central Hospital



Dr Khanyi Msomi
Dr Kerusha Govender
Dr Pravi Moodley
Dr Aabida Khan
Dr Lili Gounder
Dr Kerri Francois
Dr Cherise Naicker
Dr Joedene Chetty
Dr Neli Ngcaba
Dr Tshepiso Mosito
Mr Malcolm Ellapen
Mr Kubendran Reddy
The COVID-19 Bench team

University of KwaZulu-Natal & Africa Health Research Institute



KRISP at UKZN:

Tulio de Oliveira
Richard Lessels
Houriiyah Tegally
Eduan Wilkinson
Jennifer Giandhari
Sureshnee Pillay
Emmanuel James San



AHRI

Alex Sigal
Sandile Cele
Willem Hanekom

University of Stellenbosch & NHLS Tygerberg Virology



Susan Engelbrecht
Wolfgang Preiser
Gert van Zyl
Tongai Maponga
Bronwyn Kleinhans
Shannon Wilson
Karabo Phadu
Tania Stander
Kamela Mahlakwane
Mathilda Claassen
Diagnostic laboratory staff

University of Cape Town, NHLS & WCG



NHLS-UCT

Carolyn Williamson
Nei-yuan Hsiao
Diana Hardie
Kruger Marais
Stephen Korsman
Ziyaad Valley-Omar

WCG-UCT

Mary-Anne Davies
Hannah Hussey
Andrew Boulle
Masudah Paleker
Theuns Jacobs
Erna Morden



EDCTP



UCT, IDM and CIDRI-Africa

Deelan Doolabh
Arash Iranzadeh
Lynn Tyers
Innocent Mudau
Nokuzola Mbhele
Fezokuhle Khumalo
Thabang Serakge
Bruna Galvão
Arghavan Alisoltani
(U. California)

Robert Wilkinson
Darren Martin
Nicola Mulder
Wendy Burgers
Ntobeko Ntusi
Rageema Joseph
Sean Wasserman
Linda Boloko



CAPE TOWN HVTN
IMMUNOLOGY LABORATORY



science & innovation
Department:
Science and Innovation
REPUBLIC OF SOUTH AFRICA

University of the Free State



UFS

Dominique Goedhals
Armand Bester
Martin Myaga
Peter Mwangi
Emmanuel Ogunbayo
Milton Mogotsi
Makgotso Maotoana
Lutfiyya Mohamed



NHLS Division of Virology

Sabeegah Vawda
Felicity Burt
Thokozani Mkhize
Diagnostic laboratory staff



National Institute for Communicable Diseases



Centre for Respiratory Diseases & Meningitis

Jinal Bhiman
Anne von Gottberg
Thabo Mohale
Daniel Amoako
Josie Everatt
Boitshoko Mahlangu
Noxolo Ntuli
Anele Mnguni
Amelia Buys
Cardia Fourie
Noluthando Duma
Linda de Gouveia
Jackie Kleynhans
Nicole Wolter
Sibongile Walaza
Mignon du Plessis
Stefano Tempia
Mvuyo Makhasi
Cheryl Cohen

Centre for HIV and STIs

Cathrine Scheepers
Constantinos Kurt Wibmer
Thandeka Moyo
Tandile Hermanus
Frances Ayres
Zanele Molaudzi
Bronwen Lambson
Tandile Hermanus
Mashudu Madzivhandila
Prudence Kgagudi
Brent Oosthuysen
Penny Moore
Lynn Morris

NICD Groups

NICD COVID-19 response team
NICD SARS-CoV-2 Sequencing Group

Sequencing Core Facility

Zamantungwa Khumalo
Annie Chan
Morne du Plessis
Stanford Kwenda
Phillip Senzo Mtshali
Mushal Allam
Florah Mnyameni
Arshad Ismail



Zoonotic arbo and respiratory virus program

Centre for Viral Zoonoses Department Medical Virology/ NHLS Tshwane Academic division University of Pretoria



ZARV research program/UP

Marietjie Venter (Head: ZARV)
Adriano Mendes (Postdoc)
Amy Strydom (Postdoc)
Michaela Davis (MSc, intern medical scientist)



NHLS Tshwane

Prof Simnikiwe Mayaphi (HOD)

Funders:

GIZ/BMBF: African Network for Improved diagnostics and epidemiology of common and emerging infectious agents (ANDEMIA)
G7 Global Health fund, Robert Koch Institute, Dr Fabian Leendertz



Additional support and collaborators



NHLS

Koeleka Mlisana
Zinhle Makatini
Eugene Elliot
Florette K. Treurnicht
Kathleen Subramoney
Oluwakemi Laguda-Akingba
Shareef Abrahams
Greta Hoyland
Gloria Selabe
Elias Bereda
Jeannette Wadula

Hyrax Biosciences
Simon Travers

Cape Town HVTN Laboratory
Erica Anderson-Nissen
Anneta Naidoo

Ndlovu Research
Hugo Tempelman
CJ Umunnakwe

Lancet

Allison J. Glass

Ampath
Terry Marshall
Cindy van Deventer
Eddie Silberbauer

Pathcare Vermaak
Andries Dreyer
Howard Newman
Riaan Writes
Marianne Wolfaardt
Warren Lowman

Bridge-the-Gap
Raymond Rott

Cytespace Africa Laboratories
Christa Viljoen

ARC-OVI
Lia Rotherham

CAPRISA

Salim Abdool Karim
Nigel Garret

UKZN - Big Data
Francesco Pettruccione
Ilya Sinayskiy

University of Oxford
José Lourenço

FioCruz, Brazil
Vagner Fonseca
Marta Giovanetti
Luiz Carlos Junior Alcantara


Africa CDC

John Nkengasong
Sofonias Tessema


Netcare:
Richard Friedland
Craig Murphy
Caroline Maslo
Liza Sitharam

DSI
Glaudina Loots

SA MRC
Glenda Gray



South African genomes submitted per sequencing lab, 2020 and 2021 (N=18 449)



Multiple labs from NGS-SA are contributing to the sequencing effort.
Sequencing efforts have increased with the third wave.

Variants of Concern (VOC)

WHO label	Pango lineages ⁺	GISAID clade	Nextstrain clade	Additional amino acid changes monitored*	Earliest documented samples	Date of designation
Alpha	B.1.1.7 [#]	GRY	20I (V1)	+S:484K +S:452R	United Kingdom, Sep-2020	18-Dec-2020
Beta	B.1.351	GH/501Y.V2	20H (V2)	+S:L18F	South Africa, May-2020	18-Dec-2020
Gamma	P.1	GR/501Y.V3	20J (V3)	+S:681H	Brazil, Nov-2020	11-Jan-2021
Delta	B.1.617.2 [§]	G/478K.V1	21A	+S:417N	India, Oct-2020	VOI: 4-Apr-2021 VOC: 11-May-2021

<https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/> accessed 17 September 2021

*Notable spike (S) amino acid changes under monitoring, which are currently reported in a minority of sequenced samples

⁺Includes all descendant lineages.

[#]Includes all Q.* lineages in the PANGO nomenclature system.

[§]Includes all AY.* lineages in the PANGO nomenclature system.

Currently designated Variants of Interest (VOI)

WHO label	Pango* lineages	GISAID clade	Nextstrain clade	Earliest documented samples	Date of designation
Lambda	C.37	GR/452Q.V1	21G	Peru, Dec-2020	14-Jun-2021
Mu	B.1.631	GH	21H	Colombia, Jan-2021	30-Aug-2021

<https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/> accessed 17 September 2021

*Includes all descendant lineages.

Submission of routine specimens for sequencing

- representative of multiple geographic regions (provinces/districts/health facilities) from individuals of
 - all ages
 - over as many time periods during the SARS-CoV-2 epidemic in South Africa
- requested that testing laboratories in both the private and public sectors, submit respiratory samples to their closest NGS-SA sequencing laboratory on a routine basis (ideally every week) as follows, depending on the capacity of the testing laboratory:
 - All positives samples should be sent every week (NGS-SA laboratory will perform random sampling as described below) **OR**
 - A weekly selection of approximately 10%-20% of randomly selected positive samples should be sent every week. Number of selected samples will depend on the size of laboratory and how many other laboratories are drained by the submitting laboratory.

Submission of special interest specimens for sequencing

In addition to routine samples mentioned above, please send specimens separately to above and clearly marked if:

- Suspected vaccine breakthrough (≥ 14 days after vaccine), especially if hospitalised and clinically severe
- Suspected re-infection (≥ 90 days after previous episode), especially if hospitalised and clinically severe
- Prolonged shedding with high SARS-CoV-2 viral loads (i.e. Ct values less than 30 for more than 1 month post-primary diagnosis) in immunocompromised individuals
- Possible animal-to-human transmission
- Suspected cases of importation from another country, especially countries known to harbour SARS-CoV-2 variants of concern or countries with little available information
- Clusters of “unusual” cases (e.g., in terms of disease presentation, patient groups affected, etc.)